Benitec Biopharma Limited (NASDAQ:BNTC)
Industry: Healthcare

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. The company was founded in 1995 and is headquartered in Melbourne, Australia.

Current Quote*
Last: $0.670
Change: -0.038
Book: $0.608
Volume: 12,077

As Of: 10/18 13:02 ET
*Quotes delayed by 20min.

Graphs for BNTC

3 Month Graph

6 Month Graph

1 Year Graph